Please login to the form below
PI3K
This page shows the latest PI3K news and features for those working in and with pharma, biotech and healthcare.
Chi-Med cues up two more regulatory filings in cancer
Following after its first three drugs are potential first-in-class selective Syk inhibitor HMPL-523, in phase 1 testing for non-Hodgkin’s lymphoma, and a PI3K delta inhibitor
Latest news
-
FDA clears Novartis’ new breast cancer drug Piqray
Blockbuster potential for PI3K drug. Novartis has gained FDA approval for its PI3K inhibitor Piqray for advanced breast cancer, bucking the trend for the drug class in solid tumour therapy. ... Rival Swiss pharma Roche was also developing a PI3K
-
Novartis sees five new $1bn-plus launches in next two years
among PI3K inhibitors.
-
Tecentriq combo shows promise in triple negative breast cancer
Ipatasertib is an oral, targeted drug that binds to all three isoforms of AKT, which blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival. ... The molecule is being studied in tumours that are frequently found to have
-
Novartis claims a rare win at ESMO for PI3K inhibitor class
Novartis thinks could be down to its high specificity for the PI3K alpha receptor. ... Roche scrapped taselisib for breast cancer after reporting the SANDPIPER results at ASCO, but said it is still interested in pursuing the PI3K mechanism with other
-
A look ahead to key trial readouts at ESMO
In breast cancer, Novartis will be presenting its SOLAR-1 study of alpha-specific PI3K inhibitor alpelisib (BYL719) in HR+/HER2- advanced breast cancer with PIK3CA mutations, and Clovis Oncology’s
More from news
Approximately 1 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and PI3K‐gamma for haematological cancers (p3).
-
Deal Watch table for September 2014
970. Infinity / AbbVie. Licence and collaboration. IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia .
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Curis looks to MedImmune and Takeda for new hires
These include CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Merck enters agreement with Hanmi for investigational NASH drug
- Novo Nordisk growth takes a hit with China deal
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Omicron prompts global action
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- The gold standard of scientific evidence
- AbbVie creates new aesthetics division amid Allergan takeover
- EU approves bluebird bio’s CALD gene therapy Skysona
- Organon buys Forendo in $1bn deal
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
